Seek Returns

EXEL vs. GILD: Exelixis vs. Gilead Sciences Stock Comparison

How do Exelixis (EXEL) and Gilead Sciences (GILD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Exelixis (EXEL) and Gilead Sciences (GILD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Exelixis (EXEL) and Gilead Sciences (GILD)
Profile ItemEXELGILD
NameExelixis Inc.Gilead Sciences Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization16.98 billion USD207.00 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateApril 17, 2000January 22, 1992
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

EXEL
GILD
GSPC
Loading price history…
Exelixis (EXEL) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Exelixis (EXEL) and Gilead Sciences (GILD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Exelixis (EXEL) and Gilead Sciences (GILD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Exelixis (EXEL) and Gilead Sciences (GILD)
MetricEXELGILD
Total Return (1Y)74.98%45.69%
Total Return (3Y, Annualized)50.33%35.30%
Total Return (5Y, Annualized)31.10%25.00%

Risk Profile

Drawdown History

EXEL
GILD
GSPC
Loading price history…
Exelixis (EXEL) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Exelixis (EXEL) and Gilead Sciences (GILD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Exelixis (EXEL) and Gilead Sciences (GILD)
MetricEXELGILD
Volatility (1Y, Annualized)34.17%27.57%
Beta (5Y)0.410.36
Max Drawdown (5Y)-35.41%-26.59%
Avg. Volume (3M)2.33M5.98M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
EXEL and GILD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Exelixis (EXEL) and Gilead Sciences (GILD)
MetricEXELGILD
Sharpe Ratio (1Y)2.071.50
Sortino Ratio (1Y)3.232.48

Profitability

ROE (TTM)

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Exelixis (EXEL) reports 44.32%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max
109.18%
EXEL
44.32%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Exelixis (EXEL) reports 35.45%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL
35.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Exelixis (EXEL) at 40.75% and Gilead Sciences (GILD) at 42.43% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max
83.12%
EXEL
40.75%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Exelixis (EXEL) and Gilead Sciences (GILD)
MetricEXELGILD
ROE (TTM)44.32%-22.45%
ROA (TTM)23.52%13.47%
Net Margin (TTM)35.45%-12.46%
Operating Margin (TTM)40.75%42.43%
Gross Margin (TTM)96.26%79.95%

Growth

Revenue Growth

Both Exelixis (EXEL) at 6.98% and Gilead Sciences (GILD) at 2.39% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than Exelixis (EXEL) at 57.95%, which is closer to a typical peer reading.

Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Exelixis (EXEL) and Gilead Sciences (GILD)
MetricEXELGILD
Revenue Growth (YoY)6.98%2.39%
Revenue Growth (3Y CAGR)12.93%2.57%
EPS Growth (YoY)57.95%1,684.21%
EPS Growth (3Y CAGR)70.59%23.04%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Gilead Sciences (GILD) at 1.38 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GILD.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max
25.13
Q3
12.13
Median
5.52
EXEL
3.21
Q1
2.47
Min
0.10

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Exelixis (EXEL) at 0.09 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
EXEL
0.09
Q1
0.02
Min
0.00

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Exelixis (EXEL) and Gilead Sciences (GILD)
MetricEXELGILD
Current Ratio (MRQ)3.211.38
Debt / Equity (MRQ)0.092.02
Net Debt / EBITDA-0.711.25

Dividends

Dividend Yield (TTM)

Exelixis (EXEL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Exelixis (EXEL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Exelixis (EXEL) and Gilead Sciences (GILD)
MetricEXELGILD
Dividend Yield (TTM)0.00%1.94%
Dividend Payout Ratio (TTM)0.00%43.46%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Exelixis (EXEL) trades at 20.83 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max
85.34
Q3
43.46
Median
26.69
EXEL
20.83
Q1
13.30
Min
0.07

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): GILD does not report P/E ratio, so it has no value marker; EXEL is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both Exelixis (EXEL) at 6.80 and Gilead Sciences (GILD) at 6.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max
58.18
Q3
25.77
Median
7.30
EXEL
6.80
Q1
3.01
Min
0.01

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Exelixis (EXEL) at 9.28 sits in the upper P/B ratio quartile, and Gilead Sciences (GILD) at 15.88 prices even higher, above its industry range.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max
13.53
EXEL
9.28
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Exelixis (EXEL) vs. Gilead Sciences (GILD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Exelixis (EXEL) and Gilead Sciences (GILD)
MetricEXELGILD
P/E Ratio (TTM)20.83--
P/S Ratio (TTM)6.806.68
P/B Ratio (MRQ)9.2815.88
Free Cash Flow Yield (TTM)4.47%5.16%